On September 1, 2026, Hims & Hers began serving customers in Australia, its first presence in the Asia-Pacific market, by rebranding Pilot — the Sydney-based men's telehealth platform it acquired as part of Eucalyptus — as Hims. It is the first Eucalyptus brand to transition to the Hims name, and the company says existing customers keep their treatment plans and provider relationships through the switch.

Why It Matters

The sexual health business is doing something specific inside this story: it is the beachhead, not the headline. Pilot built trust in Australia on men's health, ED and hair loss, and Hims is monetizing that trust with weight-loss drugs while the sexual health catalogue rides along. That is the same sequencing Hims ran in the US — acquire the patient through a destigmatized entry point, then expand share of wallet across conditions — and it is now the template for the category's international phase. For anyone valuing sexual-health telehealth assets, the lesson is that the ED and PE franchises are being priced as customer-acquisition infrastructure rather than as standalone businesses. The margin admission matters for the broader beat. Telehealth's promise to the sexual wellness sector has always been that regulatory arbitrage and direct-to-patient economics beat clinic overhead. Hims is now publicly conceding that going international compresses gross margin, which suggests the model travels less cleanly than the pitch decks imply — local clinical standards, local prescribing rules, and local drug pricing all take a cut. And the regulatory backdrop is the thing to watch. A company expanding across Australia, Canada, the UK, Japan and the EU while facing a US securities class action, an FTC complaint, a board investigation and a senator's referral to the FDA is running a jurisdictional experiment in real time. If the US enforcement posture on subscription telehealth hardens, the international revenue Hims is buying may become load-bearing faster than planned.

The product mix is the tell. Reuters reporting carried by Inside Retail notes the launch leads with branded GLP-1 weight-loss drugs, with Pilot's existing catalogue spanning sexual health medications through to cholesterol treatments. Tim Doyle, Eucalyptus founder and former CEO, now Senior Vice President of International at Hims & Hers, said the combination "gives us a meaningful opportunity to help even more Australians access better, more comprehensive weight-loss care" and pointed to rural access as the structural problem being solved: nearly 30% of Pilot's patients live in regional and rural Australia. Hims says it plans to launch its women's health segment in Australia later this year through Juniper, Eucalyptus' women's brand, and has appointed Gus Wood as General Manager of Australia and Dr. Matt Vickers as Chief Medical Officer of Hims Australia.

The financial framing is explicit. Hims' announcement states it expects the Australian market to help it reach $1 billion in international annual revenue within three years, against a company-wide target of $6.5 billion in revenue and $1.3 billion in adjusted EBITDA by 2030. The Eucalyptus deal — funded in part by the upsized $350 million zero-coupon convertible note Hims priced in May 2026 — closed a month ahead of schedule and brought a platform that had served more than 850,000 customers as of May, with operations spanning the US, UK, Australia and Canada plus activity in France, Germany, Ireland, Spain and Japan.

International expansion is not free. Hims has said international offerings are pressuring gross margins, which it expects to remain below historical levels, even as monthly revenue per subscriber rose 21% year-over-year with international contributing. Leerink has maintained a Market Perform rating and a $25 price target, flagging uncertainty around future profits from branded GLP-1 drugs and the company's ability to convert existing US patients through the GLP-1 transition.

All of which lands while the company is under real pressure at home. Hims faces a securities class action stemming from the FTC's July 29 complaint over billing and subscription practices, with a lead plaintiff deadline of November 2, 2026, and a separate board-level fiduciary-duty investigation. Senator Jim Banks has reportedly urged the FDA to examine advertising, pricing and subscription practices at Hims and other telehealth providers.

Sources

Update — 2026-09-08

{Initial entry — story first created.}